Savolitinib Plus Osimertinib Improves PFS Over Chemotherapy in EGFR‑Mutated, MET‑Amplified NSCLC
A new combination therapy of savolitinib and osimertinib shows promise for patients with advanced non-small cell lung cancer (NSCLC). This treatment approach substantially improved progression-free survival (PFS) compared to customary chemotherapy in patients whose tumors have specific genetic characteristics: an EGFR mutation and amplification of the MET gene, and who have already progressed on EGFR tyrosine kinase inhibitor (TKI) therapy.
The findings,presented at a major medical conference and published in peer-reviewed journals,highlight a potential new oral treatment option for this challenging patient population. Currently, patients with NSCLC who develop resistance to initial EGFR TKIs and harbor MET amplification have limited effective treatment choices. Chemotherapy is often used, but it comes with significant side effects and doesn’t always provide lasting benefit.
Savolitinib is a MET tyrosine kinase inhibitor, meaning it specifically targets and blocks the activity of the MET protein. MET amplification is a known mechanism of resistance to EGFR TKIs, so inhibiting MET can restore sensitivity to these drugs. Osimertinib is a third-generation EGFR TKI, designed to overcome common EGFR mutations that cause resistance to earlier-generation TKIs. Combining the two drugs addresses both resistance mechanisms together.
In the clinical trial, patients receiving the savolitinib-osimertinib combination experienced a statistically significant improvement in PFS compared to those receiving chemotherapy. Importantly, the combination therapy maintained a favorable tolerability profile, meaning side effects were manageable. This is a crucial factor, as patients with advanced NSCLC are frequently enough frail and can struggle with the harsh side effects of chemotherapy.Merck and AstraZeneca jointly developed and studied the combination.
This biomarker-selected approach – identifying patients with specific genetic alterations – is becoming increasingly significant in cancer treatment.By targeting therapies to the patients most likely to benefit,doctors can maximize effectiveness and minimize unneeded side effects. Further research is ongoing to determine the long-term benefits of savolitinib-osimertinib and to explore its potential use in earlier lines of therapy.